Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Intraoperative High Impedance Levels During Placement of Deep Brain Stimulating Electrode
Lyons, Mark , Neal, Matthew T. , Patel, Naresh P. , Lyons, Mark K, Patel, Naresh P

Mayo Clinic

Operative Neurosurgery | March 12, 2019 | Volume: 17 | Issue: 6 | Pages: E264-E266

10.1093/ons/opz035 | PMID 30860268 Get It

Abstract BACKGROUND AND IMPORTANCE Deep brain stimulation (DBS) is a well-established treatment for medically refractory Parkinson's disease (PD), essential tremor (ET), and dystonia. The field of DBS is expanding and techniques are under investigation for the treatment of several neurological disorders. A critical component of the success of these procedures depends significantly on the reliability and durability of devices implanted. Immediate feedback during surgery often gives the surgeon and patient a sense of confidence of long term success. When impedances are found to be elevated during the implantation of the DBS leads, appropriate trouble shooting measures are critical. CLINICAL PRESENTATION We present a 73-yr-old male undergoing awake subthalamic DBS with microelectrode recordings for severe PD. Once the optimal trajectory and depth were ascertained, the permanent DBS electrode was placed. High impedances were recorded. Troubleshooting procedures were performed and were all negative as to the cause of the values. Correct impedance levels of the DBS electrode was confirmed with extracranial testing, but continued high values were found again with intracranial positioning of the electrode. A postoperative computerized tomography (CT) scan confirmed intracranial air surrounding all of the contacts. The patient went on to outpatient programming with excellent clinical results. CONCLUSION The presence of pneumocephalus surrounding the DBS lead contacts at the target nucleus may have accounted for the intraoperative impedance findings. When all troubleshooting checks have not identified an explanation for the high impedances, intraoperative imaging may demonstrate pneumocephalus around the lead contacts, which should resolve and impedances return to normal values.
Comparison of the NCCN‐IPI, the IPI and PIT scores as prognostic tools in peripheral T‐cell lymphomas
Ellin, Fredrik , Maurer, Matthew J. , Srour, Line, Farooq, Umar , Smedby, Karin E. , Ansell, Stephen M. , Slack, Graham W. , Relander, Thomas, Cerhan, James R , Savage, Kerry J , Maurer, Matthew , Farooq, Umar , Jerkeman, Mats , Connors, Joseph M. , Bennani, N. Nora , Cerhan, James R. , Feldman, Andrew L. , Savage, Kerry J.

Mayo Clinic

British Journal of Haematology | March 12, 2019 | Volume: 186 | Issue: 3 | Pages: No page available

10.1111/bjh.15859 | PMID 30859549 Get It

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
Shroff, Rachna T. , Kennedy, Erin B. , Bekaii‐Saab, Tanios , Crane, Christopher H. , Feng, Mary, Katz, Matthew H. G. , Primrose, John , Bekaii-Saab, Tanios S , Katz, Matthew H G , Bachini, Melinda , Edeline, Julien , El-Khoueiry, Anthony B. , Soares, Heloisa P. , Valle, Juan W. , Maithel, Shishir K

Mayo Clinic

Journal of Clinical Oncology | March 11, 2019 | Volume: 37 | Issue: 12 | Pages: 1015-1027

10.1200/jco.18.02178 | PMID 30856044 Get It

PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated m
Somlo, George, Frankel, Paul , Luu, Thehang, Cynthia, X. , García, Agustin A. , Cigler, Tessa, Cream, Leah, Harvey, Harold A., Nanda, Rita , Chew, Helen K. , Moynihan, Timothy J. , Hurria, Arti , Chen, Alice P. , Arun, Banu , Sparano, Joseph A. , Vahdat, Linda T. , Goetz, Matthew P. , Mortimer, Joanne , Gandara, David R. , Weitzel, Jeffrey N.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 520-520

10.1200/jco.2015.33.15_suppl.520 Get It

The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease
Whitwell, Jennifer L. , Martin, Peter R. , Graff‐Radford, Jonathan, Senjem, Matthew L. , Weigand, Stephen D. , Spychalla, Anthony J., Drubach, Daniel A., Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Jack, Clifford R , Senjem, Matthew L , Graff‐Radford, Jonathan , Machulda, Mary M. , Schwarz, Christopher G.

Mayo Clinic

Alzheimer's & Dementia | March 7, 2019 | Volume: 15 | Issue: 5 | Pages: 675-685

10.1016/j.jalz.2018.12.016 | PMID 30853465 Get It

AbstractIntroductionLittle is known about the role of age on neurodegeneration and protein deposition in atypical variants of Alzheimer's disease (AD).MethodsRegional tau and β‐amyloid positron emission tomography standard uptake value ratios and gray matter volumes were calculated in a cohort of 42 participants with atypical AD. The relationship between regional metrics and age was modeled using a Bayesian hierarchical linear model.ResultsAge was strongly associated with tau uptake across all cortical regions, particularly parietal, with greater uptake in younger participants. Younger age was associated with smaller parietal and lateral temporal volumes. Regional β‐amyloid differed little by age. Age showed a stronger association with tau than volume and β‐amyloid in all cortical regions. Age was not associated with cognitive performance.DiscussionAge is an important determinant of severity of cortical tau uptake in atypical AD, with young participants more likely to show widespread and severe cortical tau uptake.
Disease-specific hashtags for online communication about cancer care.
Johnston, Claire , Aase, Lee , Lee, Thomas , Dizon, Don S. , Katz, Matthew S. , Utengen, Audun , Anderson, Patricia F , Thompson, Michael A. , Fisch, Michael , Johnston, Claire, Attai, Deanna J. , Miller, Robert S.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6520-6520

10.1200/jco.2015.33.15_suppl.6520 Get It

Coordinated follow-up Breast Cancer Survivorship Care Program study.
Ruddy, Kathryn J. , Baker, Emily, Goldstein, Matthew , Mullaney, Erin E., Shulman, Lawrence N. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e17727-e17727

10.1200/jco.2015.33.15_suppl.e17727 Get It

Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.
Ahmad, Syed A. , Marsh, Robert , Collisson, Eric A. , Schwartz, Lawrence H., Martin, Robert C.G. , Conway, William, Truty, Mark J. , Kindler, Hedy L. , Lowy, Andrew M. , Philip, Philip Agop, Cardin, Dana B. , LoConte, Noelle K. , Cardin, Dana B , LoConte, Noelle , Katz, Matthew H. G. , Shi, Qian , Herman, Joseph M. , Bekaii‐Saab, Tanios , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4008-4008

10.1200/jco.2015.33.15_suppl.4008 Get It

Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. , Fruth, Briant, Kunz, Pamela L. , Kennecke, Hagen F. , Wolin, Edward M. , Niedzwiecki, Donna , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4005-4005

10.1200/jco.2015.33.15_suppl.4005 Get It